Evercore ISI initiated coverage on Mineralys Therapeutics
$MLYS
Biotechnology: Pharmaceutical Preparations
Health Care
Evercore ISI initiated coverage of Mineralys Therapeutics with a rating of Outperform
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 6/11/2025 | $15.00 | Hold | Jefferies |
| 7/10/2024 | $30.00 | Buy | H.C. Wainwright |
| 4/2/2024 | $30.00 | Buy | Goldman |
| 3/7/2023 | Outperform | Evercore ISI | |
| 3/7/2023 | $39.00 | Buy | BofA Securities |
| 3/7/2023 | $32.00 | Buy | Guggenheim |
| 3/7/2023 | $27.00 | Overweight | Wells Fargo |
| 3/7/2023 | $45.00 | Buy | Stifel |
4 - Mineralys Therapeutics, Inc. (0001933414) (Issuer)
4 - Mineralys Therapeutics, Inc. (0001933414) (Issuer)
4 - Mineralys Therapeutics, Inc. (0001933414) (Issuer)
8-K - Mineralys Therapeutics, Inc. (0001933414) (Filer)
144 - Mineralys Therapeutics, Inc. (0001933414) (Subject)
8-K - Mineralys Therapeutics, Inc. (0001933414) (Filer)
4 - Mineralys Therapeutics, Inc. (0001933414) (Issuer)
4 - Mineralys Therapeutics, Inc. (0001933414) (Issuer)
4 - Mineralys Therapeutics, Inc. (0001933414) (Issuer)
Jefferies initiated coverage of Mineralys Therapeutics with a rating of Hold and set a new price target of $15.00
H.C. Wainwright initiated coverage of Mineralys Therapeutics with a rating of Buy and set a new price target of $30.00
Goldman initiated coverage of Mineralys Therapeutics with a rating of Buy and set a new price target of $30.00
– Explore-CKD met its primary endpoint; lorundrostat 25 mg once daily achieved a 9.3 mmHg reduction in systolic blood pressure, and a 7.5 mmHg placebo-adjusted reduction (p=0.0024) at four weeks – – Lorundrostat showed a clinically meaningful reduction in the pre-defined endpoint spot urine albumin-to-creatinine ratio of 31% (p<0.0001) – – Lorundrostat demonstrated a favorable safety and tolerability profile – – Conference call today at 8:00 a.m. ET – RADNOR, Pa., June 17, 2025 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ:MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD), obstructive sleep
– Largest hypertension trial of an aldosterone synthase inhibitor to date demonstrated the efficacy of lorundrostat in over 1,000 participants with uncontrolled or resistant hypertension in a real-world setting – – Lorundrostat 50 mg dosed once daily demonstrated clinically meaningful and sustained reductions in systolic blood pressure, with a 16.9 mmHg reduction at Week 6 (-9.1 mmHg placebo adjusted) and a 19.0 mmHg reduction at Week 12 (-11.7mm placebo adjusted) – – Lorundrostat demonstrated a favorable safety and tolerability profile – RADNOR, Pa., May 24, 2025 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ:MLYS), a clinical-stage biopharmaceutical company focused on deve
RADNOR, Pa., May 20, 2025 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ:MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases driven by dysregulated aldosterone, today announced that data from the pivotal Phase 3 Launch-HTN trial evaluating the efficacy and safety of lorundrostat for the treatment of uncontrolled hypertension (uHTN) or resistant hypertension (rHTN) will be presented in a late-breaking clinical trials session at the 34th European Meeting on Hypertension and Cardiovascular Protection (ESH 2025), which will be held in Milan at the MICO